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Abstract
Background: Haemophilus influenzae type b (Hib) vaccination led to a significant decrease in
invasive bacterial infections in children. The aim of this study was to assess a potential shift to more
non-type b invasive infections in a population with high Hib vaccination coverage and to compare
the burden of suffering between children with Hib, capsulated non-b and non-capsulated Hi
infections.
Methods: Cases with confirmed invasive Hi infections were ascertained through two independent
nationwide active surveillance systems in 1998–2005. Information on possible predisposing
conditions and clinical information was available from 2001 onwards.
Results: The total number of reported non-type b Hi cases varied between 10 cases in 1998, 27
in 2000 and 14 in 2005. In each year, non-capsulated serotypes outnumbered capsulated non-type
b ones. 192 cases were detected in 2001–2005, more than one half was non-type b and 88% of the
non-type b cases were non-capsulated. For cases with Hib/capsulated non-type b infections the
most common clinical presentation was meningitis (67% each); 89%/78% had no potential
predisposing condition, 75%/72% completely recovered from disease and 6% (each) died. In
contrast, meningitis was diagnosed in 34% of the non-capsulated Hi infections, septicaemia in 28%
and pneumonia 21%; 62% had no potential predisposing condition, 83% completely recovered and
3% died.
Conclusion: There was no increase in non-type b Hi invasive infections during 8 years of active
surveillance in Germany. Invasive disease due to non-type b Hi is not confined to children with risk
factors. In patients with capsulated non-type b Hi infections the proportion of meningitis cases is
similar to Hib, but double as high as in non-capsulated Hi.
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Background
Prior to the development of effective vaccines, Haemo-
philus influenzae (Hi) was one of the most important
organisms causing invasive bacterial infections in chil-
dren in developed countries [1-3]. The predominant sero-
type causing invasive disease in children was type b (Hib).
In Europe, the annual incidence rate of invasive Hib in
children less than five years ranged between 20 and 50 per
100,000, with non-type b serotypes being only of anec-
dotic interest [4-8].
Due to the introduction of conjugate vaccines against Hib
the incidence of Hib infections decreased sharply in most
countries worldwide [5,9-11]. In Germany, Hib conjugate
vaccines were introduced in July 1990 and were subse-
quently combined with diphtheria, tetanus and acellular
pertussis antigens (DTaP/Hib) and higher-valent vaccines,
additionally incorporating inactivated polio virus and
hepatitis B (DTaP-IPV-HB/Hib). All licensed Hib vaccines
in Germany are well tolerated and effective [12] against
invasive Hib infections and Hib vaccine coverage rates are
high (e.g. 84% of 24-month-old children born 2002–
2003 received three doses [13]).
There have been relatively few published studies on the
impact of Hib vaccination on the emergence of non-type
b invasive Hi infections in children [14-21]. In 2007, a
study conducted between 1996 and 2001 in 12 Canadian
paediatric tertiary care centres during the era of universal
immunisation against Hib showed that two-third of Hi
invasive infections were caused by non-b serotypes and
that annual numbers of non-type b invasive infections
increased over the years[16]. These non-b serotypes pre-
sented with significant morbidity and mortality.
The aim of this population based study in Germany was
to assess whether a similar increase in non-type b Hi inva-
sive infections can be confirmed in 1998–2005, and to
describe the burden of suffering related to non-type b Hi
invasive disease as compared to Hib invasive disease in
children less than 10 years.
Methods
Case definition
Definition of invasive Haemophilus influenzae (Hi) cases
required hospitalisation for a systemic infectious disease
(e.g. meningitis, pneumonia, epiglottitis, septicaemia, cel-
lulitis, septic arthritis) in paediatric hospitals in Germany
with isolation of Hi from a normally sterile body site such
as blood or cerebrospinal fluid.
Data sources
Cases of invasive Hi infections in children younger than
10 years were collected from a hospital-based surveillance
system (Hospital-ESPED) and a laboratory-based surveil-
lance system (Laboratory-ESPED) over the period 1998–
2005. Both systems are voluntary but require active
reporting: the absence of cases has to be reported as well
and reminders for missing reports are included on a
monthly basis.
In Hospital-ESPED, physicians from all paediatric hospi-
tals in Germany report incident cases of a number of rare
conditions on a monthly basis since 1992 to a central
study office[22]. Reporting on Hi was included since
1998. These reports provide information on an identifica-
tion number for Hospital-ESPED, location of the report-
ing hospital, date of birth, age at disease onset, sex, date of
disease onset, bacteriologic serotype, detection material,
potential predisposing conditions and outcome as well as
vaccination information.
For isolation of respective pathogens paediatric hospitals
send specimen of body tissue to microbiological laborato-
ries. From 1998–2005, all laboratories throughout Ger-
many serving the paediatric hospitals were asked to report
any detection of Hi in physiologically sterile materials in
children to Laboratory-ESPED. Collected data were com-
parable to Hospital-ESPED: identification number for the
sample as given by the laboratory, patient's month and
year of birth, 3-digit postal code of patient's residence, sex,
date of sample arrival at laboratory, bacteriologic sero-
type, material, and whether an isolate was sent to the
National H. influenzae Consulting Laboratory for capsule
typing, and bacteriologic serotype if available. From 2001
onwards, possible predisposing conditions and clinical
information, were also collected by tracing each patient
back to the reporting hospital [23].
Cultural confirmation was performed in the local labora-
tories participating in the surveillance programme accord-
ing to their routine procedures. Local laboratories also
performed PCR testing for capsule type on recovered iso-
lates when available. Laboratories were encouraged to
send their specimens to the National H. influenzae Con-
sulting Laboratory at the Department of Paediatric Infec-
tious Diseases, Johannes-Gutenberg-University, Mainz,
Germany. Capsular typing was performed by slide agglu-
tination using a commercial kit (Haemophilus influenzae
Agglutinating Sera (a-f); Murex Biotech Ltd., Dartford,
UK). The capsular type was confirmed by molecular typ-
ing with the primers and methods recommended by the
European Haemophilus Reference Unit [24]. First, the cap-
sular gene bexA and the b-specific capsular gene were
detected by PCR in order to identify b--mutants. If bexA
was present the specific gene for the capsular types a-f was
detected by PCR. The biotype was determined as
described by Kilian [25]. If slide agglutination and PCR
results were discordant, PCR results were considered final.
If samples for the case were not sent to the reference labo-BMC Infectious Diseases 2009, 9:45 http://www.biomedcentral.com/1471-2334/9/45
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ratory but local typing results were available, they were
considered final; if samples for the case were sent to the
reference laboratory, the reference laboratory results are
considered final. If no typing was performed, the case is
considered "untyped".
The linkage between the two sources was done by hand
applying defined matching rules and using the following
patient characteristics: month and year of birth, sex,
region of residence (ie, county and federal state vs. address
of the hospital), and date of disease onset.
Analyses
To describe annual trends in the different Hi serotypes we
used all cases detected in the two surveillance systems
from January 1998 to December 2005. Trends in cases
with Hib, non-type b and untyped Hi infections were ana-
lysed using a Poisson model. Differentiation in capsulated
and uncapsulated non-type b cases was not performed
due to the low number of capsulated cases. Since informa-
tion on potential predisposing conditions and clinical
outcome was only available from January 2001 onwards
for both sources, we restricted the description of the clin-
ical characteristics for the different serotypes to those
cases. For comparison between children with Hib, capsu-
lated non-b and uncapsulated infections, a global test of
difference was performed. If results were significant (p <
0.001), cases with capsulated and uncapsulated non-type
b infections were pairwise compared to cases with Hib
infections.
The study received the positive vote by the ethics commit-
tee of the medical faculty of the Ludwig-Maximilians Uni-
versity, Munich.
Results
Characteristics of the surveillance systems
Response rates per year ranged between 95% and 98% for
Clinical ESPED and between 94% and 100% for Labora-
tory ESPED. Clinical ESPED detected between 47%
(2005) and 66% (2003) of all reported children with
invasive Hi disease, and Laboratory ESPED between 79%
(2000) and 98% (2001). Serotyping was performed by
the National H. influenzae Consulting Laboratory between
64% (2000) and 79% (2005) of all Hi cases per year.
Annual trends of Hi cases
The total number of reported cases decreased from 51
children in 1998 to 32 in 2005 (Fig. 1). The number of
untyped serotypes decreased from 13 cases in 1998 to 6
cases in 2005 (p < 0.001). Overall, type b cases decreased
from 28 in 1998 to 12 in 2005 (p < 0.001). There was no
trend for non-type b cases (p = 0.771). In most years non-
b Hi serotypes outnumbered Hib serotypes, with the
exception of 1998, 1999 and 2003. In each year, non-cap-
sulated serotypes outnumbered capsulated non-type b
ones (0–5 capsulated non-type b vs. 10–24 non-capsu-
lated per year).
Clinical characteristics of the different serotypes since 
2001
In total, 192 cases of invasive Hi in children were detected
from January 2001 to December 2005. Serotyping was
performed in 157 of the 192 reported cases (82%). Over-
all 64 cases were determined to be type b and 93 to be
non-type b. Of the 93 non-type b cases, 18 were capsu-
lated, 70 were non-capsulated (a-f negative) and 5 cases
were not further specified.
Table 1 summarises the possible predisposing conditions,
diagnostic characteristics, and vaccination status of the
different Hi serotypes.
Serotype b
Of the 64 Hib cases, median age (10th – 90th percentile) at
disease onset was 11 (3–40) months. The most common
clinical presentation was meningitis, followed by epiglot-
titis and pneumonia. Potential predisposing conditions
were reported in 7 children (11%): 3 with prematurity, 1
child with immunsuppressive therapy, 2 with Down syn-
drome, and 1 with suspected cerebrospinal fluid (CF) fis-
tula. 48 of the 64 Hib cases completely recovered from
acute infection without any obvious sequelae and 4 chil-
dren died. All children with fatal outcome had meningitis.
For 45 of the 64 Hib cases the specific biotype was meas-
ured: 31 had biotype I (68.9%), 13 biotype II (28.9%)
and 1 (2.2%) biotype VII. Vaccination status was known
for all but one Hib case. 40 were not vaccinated and 23
were vaccinated at least once before disease onset. Of the
23 vaccinated cases, 6 were considered to be vaccine fail-
ures of the incomplete primary vaccination schedule, 10
were considered to be vaccine failures of the primary vac-
cination schedule (2 or 3 doses in the first year of life,
depending on the vaccine used) and 7 were considered to
be vaccine failures of the full immunisation schedule (pri-
mary vaccination plus booster dose or a single dose in the
second year of life). Four of the 23 vaccinated cases were
reported to have potential predisposing conditions
(17%). None of the vaccinated Hib cases died.
Capsulated non-b serotypes
Of the 18 capsulated non-type b cases, 15 were type f and
1 each was type a, type c and type e. Median age (10th –
90th percentile) at disease onset was 31 (5–68) months.
The most common clinical presentation was meningitis,
followed by pneumonia and septic arthritis. For 4 of the
18 children (22%) potential predisposing conditions
were reported: one child with congenital rubella syn-
drome, one with orofaciodigital syndrome, one with cer-BMC Infectious Diseases 2009, 9:45 http://www.biomedcentral.com/1471-2334/9/45
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ebrofluid fistula, one with concurrent varicella infection.
13 of the 18 cases completely recovered from acute infec-
tion without any obvious sequelae and 1 child died. This
5 month-old girl had meningitis due to a type a infection
and no predisposing condition.
For 17 of the 18 capsulated non-b cases the specific bio-
type was measured: 10 hadbiotype I (58.8%), 5 biotype II
(29.4%) 1 biotype III (5.9%) and 1 (5.9%) biotype IV.
Non-capsulated serotypes
Of the 70 non-capsulated cases, median age (10th – 90th
percentile) at disease onset was 26 (0–73) months. The
most common clinical presentation was meningitis, fol-
lowed by septicaemia without detectable focus and pneu-
monia. However, meningitis was less common in
uncapsulated serotypes compared to Hib serotypes (p <
0.0001). For 25 children (38%) potential predisposing
conditions were reported: 12 prematurity, 5 immunodefi-
ciency and/or immunsuppressive therapy, 1 Down syn-
drome, 3 suspected CF fistula, 1 recurrent pneumonia, 1
gangliosidosis, 1 RSV infection, 1 cardial malformation.
83% of cases completely recovered from acute infection
without any obvious sequelae. 2 children died, a preterm
(29th week of pregnancy) girl with sepsis and a 22-month
old boy with meningitis with a medical history of immu-
nodeficiency. This proportion is lower than in cases with
capsulated Hi infections but this difference did not reach
statistical significance.
11 of the 70 non-capsulated children with invasive dis-
ease had biotype I (15.7%), 31 biotype II (44.3%) 18 bio-
type III (25.7%), 8 biotype V (11.4%) and 2 biotype VIII
(2.9%).
Discussion
Annual trend in non-b Hi serotypes
We found no increase of invasive diseases in children
caused by non-type b Hi serotypes in a nationwide active
surveillance system covering eight years of the post-vac-
cine-period. This is in contrast to a recently published
Canadian study conducted between 1996 and 2001 dur-
ing the era of universal immunisation against Hib show-
ing that annual numbers of non-type b invasive disease
increased over the years [16]. Further literature on the
impact of Hib vaccination on the emergence of non-type
Annual number of invasive H. influenzae cases by serotype detected from 1998 to 2005 Figure 1
Annual number of invasive H. influenzae cases by serotype detected from 1998 to 2005.
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b isolates as invasive pathogens in children is scarce, but
almost all of them showed no increase of non-b serotypes
in young children [14,15,17,18,20,21]. An exception is a
study done by Ribeiro and colleagues [19], who described
an increase of type a Hi invasive infections from 0.02 per
100,000 person years in the year before Hib vaccine intro-
duction to 0.16 per 100,000 person years one year after
introduction. Since this 'trend' is based on one single year
after vaccine introduction, the interpretation of these data
should be done with caution.
Relevance of non-b Hi serotypes
Non-capsulated Hi
In our study, non-b serotypes accounted for the majority
of invasive cases. Almost 80% of these were typed as being
non-capsulated. Patients infected with non-capsulated
serotypes had less meningitis than patients with Hib
infections, and the proportion of children with predispos-
ing conditions was higher. Nevertheless, two third had no
predisposing conditions, one third suffered from menin-
gitis, 3% died and 22% had serious sequelae. These results
are in accordance with the Canadian study [16]. Other
studies found a higher case fatality rate [26] and more
than 40% were preterm children [15]. In contrast to cases
with capsulated Hi infections, biotype II was the most fre-
quently found non-capsulated subtype in our study. This
biotype had so far been described as a common subtype
that is less virulent and mostly associated with non-inva-
sive disease [27,28]. However, changing virulence factors
of non-capsulated serotypes in the post-vaccine era have
been discussed [29].
Capsulated Hi
The predominant capsulated non-b serotype found in our
study was type f (83% of all capsulated non-b serotypes),
whereas in the Canadian study type a was the most com-
mon capsulated type (60%), followed by type f (26%).
The clinical picture of invasive diseases caused by these
capsulated non-b serotypes was similar to Hib concerning
the severity of the disease (2/3 with meningitis) and out-
come (1/5 with sequelae and 6% died). Although there
were more predisposing conditions observed and the
mean age at infection was higher than for Hib cases, this
effect was not statistically significant.
Table 1: Characteristics of H. influenzaecases by serotype detected from 2001 to 2005 (n = 192).#
Number cases/examined cases (% or 10–90th percentile) Type b
N = 64
Non-type b – capsulated
N = 18
Non-type b – uncapsulated
N = 70
Median age at disease onset
(10–90th percentile)
11 (3–40) 31(5–68) 26 (0–73)
Male sex 36/64 (56%) 9/18 (50%) 49/70 (70%)
Diagnosis
Meningitis 43/64 (67%) 12/18 (67%) 23/68 (34%)***
Pneumonia 5/64 (8%) 3/18 (17%) 14/68 (21%)*
Epiglottitis 6/64 (9%) 0/18 (0%) 0/68 (0%)**
Septic arthritis 1/64 (2%) 1/18 (6%) 0/68 (0%)
Osteomyelitis 1/64 (2%) 0/18 (0%) 0/68 (0%)
Other foci 4/64 (6%) 1/18 (6%) 12/68 (18%)
Septicaemia without focus 4/64 (6%) 1/18 (6%) 19/68 (28%)*
No underlying disease 56/63 (89%) 14/18 (78%) 40/65 (62%)***
Outcome
recovery 48/64 (75%) 13/18 (72%) 52/63 (83%)
sequelae 12/64 (19%) 4/18 (22%) 9/63 (14%)
Death 4/64 (6%) 1/18 (6%) 2/63 (3%)
Biotype
I 31/45 (69%) 10/17 (59%) 11/70 (16%)***
II 13/45 (29%) 5/17 (29%) 31/70 (44%)
III 0/45 (0%) 1/17 (6%) 18/70 (26%)
IV 0/45 (0%) 1/17 (6%) 0/70 (0%)
V 0/45 (0%) 0/17 (0%) 8/70 (11%)*
Other 1/45 (2%) 0/17 (0%) 2/70 (3%)*
# if global tests were significant (p < 0.001), capsulated and uncapsulated non-type b cases were pairwise compared to type b cases (* p < 0.05, ** p 
< 0.01, *** p < 0.001).BMC Infectious Diseases 2009, 9:45 http://www.biomedcentral.com/1471-2334/9/45
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Strengths and Limitations
Unlike the Canadian study, which was based on 12 paedi-
atric tertiary care centres, our study was based on a popu-
lation-wide active surveillance system including all levels
of care hospitals. Additionally, we used two independent
surveillance systems assuring a high completeness of case
detection. Capture-recapture estimates for three surveil-
lance systems reporting Hi in Germany and covering years
2001–2005 showed that the two sources, Laboratory- and
Hospital-ESPED, detected 83% of all Hi cases [30].
In many surveillance systems, it is very difficult to ensure
consistency of case ascertainment over long periods of
time because reporting and typing of cases changes over
time. In the data presented, response rates to both surveil-
lance systems were high [12,22] and remained relatively
constant, but typing of cases changed between 1998 and
2005. A decrease in typing rates could mask a "true"
increase of non-type b serotypes. That was not the case:
typing rates increased between 1998 and 2005.
We have covered a post-vaccine period of eight years in
our study. A potential limitation is the unavailability of
detailed data on the situation before the introduction and
following the first years after the introduction of Hib vac-
cines in Germany. Nevertheless, McConnell and co-work-
ers [16] found increasing numbers of non-b serotypes 10
years after the licensure of the first polysaccharide Hib
vaccine and 4 years after the implementation of Hib con-
jugate vaccines in infancy in all territories of Canada.
Conclusion
There was no increase in non-type b Hi invasive disease
during 8 years of active surveillance in Germany. Severe
invasive disease due to non-type b Hi is not confined to
children with predisposing conditions. Severity of capsu-
lated non-type b Hi infections is similar to Hib whereas
the proportion of meningitis in non-capsulated cases was
half of that in Hib cases.
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